Single-Cell RNA Sequencing for Multiple Myeloma Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack the depth and accuracy needed to molecularly define malignant cells and pathways driving multiple myeloma residual disease progression, resistance, and relapse, particularly in patients with early treatment resistance or relapse, necessitating new tools for risk stratification and therapeutic response prediction.
Innovation Solution
A method involving the determination of gene expression levels in plasma cells using single-cell RNA sequencing to identify specific genes associated with poor prognosis or treatment responsiveness, combined with the use of proteasome inhibitors and agents that down-regulate PPIA and RRM2 to treat multiple myeloma, particularly in patients with primary resistance or early relapse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current technologies are used to characterize multiple myeloma, then existing diagnostic capabilities are maintained, but the depth, resolution and accuracy needed to molecularly define malignant cells and pathways driving residual disease progression, resistance and relapse are insufficient
Solution Approach 1:
The patent applies segmentation by transitioning from bulk tissue analysis to single-cell RNA sequencing, dividing the complex tumor heterogeneity into individual cellular units for precise molecular characterization. This enables accurate identification of malignant plasma cells and their specific gene expression profiles, resolving the technical contradiction between measurement precision and detection difficulty.
Solution Approach 2:
The patent employs parameter changes by utilizing gene expression level measurements as molecular parameters to define malignant cells and predict treatment response. By measuring and analyzing specific gene expression parameters in single cells, the invention achieves high accuracy in molecular definition and prognosis without requiring overly complex detection methods.
2Reliability
If proteasome inhibitors are used to treat multiple myeloma, then treatment effectiveness is improved, but resistance development occurs leading to poor prognosis in primary resistant and early relapse patients
Solution Approach 1:
The patent applies preliminary action by using single-cell RNA sequencing to identify patients at risk of developing resistance to proteasome inhibitors before treatment begins. By detecting specific gene expression patterns in malignant plasma cells, the invention enables pre-treatment risk stratification, allowing clinicians to select alternative therapies or combination regimens for high-risk patients before resistance develops, thereby maintaining treatment effectiveness and extending response duration.
Data Source
AI summary
A method of prognosing a subject diagnosed with multiple myeloma (MM) is provided. Also provided a method of treating a subject diagnosed with MM selected expressing intracellular PPIA and/or RRM2 above a predetermined threshold, the method comprising administering to the subject a therapeutically effective amount of at least one agent which specifically down-regulates activity or expression of PPIA and/or RRM2, thereby treating the subject.